Trevi Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Trevi Therapeutics (TRVI) PT Raised to $23 at Oppenheimer
June 2, 2025 4:03 PM EDTOppenheimer analyst Leland Gershall raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $23.00 (from $20.00) while maintaining a Outperform rating.
The analyst comments "Further detail to this morning's positive topline Phase 2b announcement per the company's webcast with KOL and slides... More
